RT Journal Article
SR Electronic
T1 Longitudinal Digital Phenotyping of Multiple Sclerosis Severity Using Passively Sensed Behaviors and Ecological Momentary Assessments
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.02.24316647
DO 10.1101/2024.11.02.24316647
A1 Xia, Zongqi
A1 Chikersal, Prerna
A1 Venkatesh, Shruthi
A1 Walker, Elizabeth
A1 Dey, Anind
A1 Goel, Mayank
YR 2024
UL http://medrxiv.org/content/early/2024/12/08/2024.11.02.24316647.abstract
AB Background Longitudinal tracking of multiple sclerosis (MS) symptoms in an individual’s own environment may improve self-monitoring and clinical management for people with MS (pwMS).Objective We present a machine learning approach that enables longitudinal monitoring of clinically relevant patient-reported symptoms for pwMS by harnessing passively collected data from sensors in smartphones and fitness trackers.Methods We divide the collected data into discrete periods for each patient. For each prediction period, we first extract patient-level behavioral features from the current period (action features) and the previous period (context features). Then, we apply a machine learning (ML) approach based on Support Vector Machine with Radial Bias Function Kernel and AdaBoost to predict the presence of depressive symptoms (every two weeks) and high global MS symptom burden, severe fatigue, and poor sleep quality (every four weeks).Results Between November 16, 2019, and January 24, 2021, 104 pwMS (84.6% women, 93.3% non-Hispanic White, 44.0±11.8 years mean±SD age) from a clinic-based MS cohort completed 12-weeks of data collection, including a subset of 44 pwMS (88.6% women, 95.5% non-Hispanic White, 45.7±11.2 years) who completed 24-weeks of data collection. In total, we collected approximately 12,500 days of passive sensor and behavioral health data from the participants. Among the best-performing models with the least sensor data requirement, ML algorithm predicts depressive symptoms with an accuracy of 80.6% (35.5% improvement over baseline; F1-score: 0.76), high global MS symptom burden with an accuracy of 77.3% (51.3% improvement over baseline; F1-score: 0.77), severe fatigue with an accuracy of 73.8% (45.0% improvement over baseline; F1-score: 0.74), and poor sleep quality with an accuracy of 72.0% (28.1% improvement over baseline; F1-score: 0.70). Further, sensor data were largely sufficient for predicting symptom severity, while the prediction of depressive symptoms benefited from minimal active patient input in the form of response to two brief questions on the day before the prediction point.Conclusions Our digital phenotyping approach using passive sensors on smartphones and fitness trackers may help patients with real-world, continuous, self-monitoring of common symptoms in their own environment and assist clinicians with better triage of patient needs for timely interventions in MS (and potentially other chronic neurological disorders).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially funded by a Department of Defense grant and the National Institute of Health grants.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the University of Pittsburgh gave ethical approval for this work. Ethics committee/IRB of Carnegie Mellon University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.MSMultiple SclerosisEMAEcological Momentary AssessmentspwMSPeople with Multiple SclerosisPHQ-9Patient Health Questionnaire-9MSRS-RMultiple Sclerosis Rating Scale RevisedMFIS-5Modified Fatigue Impact Scale-5PSQIPittsburgh Sleep Quality IndexMLMachine LearningHRHeart rate